Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma

Abstract

High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed.

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma

“…The results published by Davies et al (2004) and our data suggest that 131 I-tositumomab RIT is at least equivalent to 90 Yibritumomab tiuxetan (Zevalin s ) (Gordon et al, 2004b). Indeed, in the rituximab refractory setting, efficacy may be more favourable for 131 I-tositumomab when reviewing two separate phase II studies of both these agents.…”

“…The CR rate was 20% in the pivotal study, and half of these complete responders remained disease free for more than 4 years (Kaminski et al, 2001). A more recent report (Davies et al, 2004) showed 20 CR/CRu (49%) out of 41 patients treated, with a median duration of the CR/CRu not yet reached, but will exceed 2.5 years. Our results compare well with these previous studies, showing 50% CR/ CRu, the median PFS for these patients being not reached after a median follow-up of 44 years.…”

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

“…Bringing I 131 tositumomab forward in the therapeutic schema to a less heavily pretreated population, the results of a phase II of patients treated at first or second recurrence of indolent or transformed indolent lymphoma have been reported (Davies et al, 2004). The majority of the 41 patients (71%) had follicular lymphoma, the remaining other indolent histologies (12%) or transformed disease (17%).…”

“…This approach is attractive as initial tumour debulking may result in optimal circumstances for RIT success (Kaminski et al, 2000;Davies et al, 2004), and may also permit clearance of the bone marrow thus improving haematological tolerance. This strategy should also permit RIT in candidates previously ineligible because of heavy marrow infiltrate.…”

“…The relative immunocompetency of the patient is a major determinant of HAMA development; in the previously untreated patients the rate was very much higher at 63% (Kaminski et al, 2005b). The consequence of HAMA development is unclear, and does not appear to compromise response to therapy (Davies et al, 2004). The rate of HAMA is much lower following Y 90 ibritumomab tiuxetan, at 1% (Witzig et al, 2003b); in the latter regimen, exposure to murine protein in less.…”